ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Demonstration project to yield useful data, Peter Bach says.

June 3, 2005

Trial Shows Standard-Dose Radiotherapy Safer, More Effective than Higher Doses

May 31, 2013

Rising Obesity May Result In Higher Cancer Incidence

August 27, 2010

Blochs to Sponsor “Fighting Cancer”

May 9, 1986

In Brief: Million, Donaldson Head ASTRO; James Weese Moves To Presbyterian; Ginder Replaces Kennedy

November 9, 1990

Chemosensitivity, Resistance Assays Not Ready For Clinic, ASCO Tech Assessment Says

August 27, 2004